Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Depression 6Neoplasms 5Anxiety Disorders 5Melanoma 2Depressive Disorder, Major 2Pain 1Osteosarcoma 1Opioid-Related Disorders 1Neoplasm Metastasis 1Lymphoma 1Hospice 1Hematopoietic and Lymphatic System Neoplasm 1Endocrine Gland Neoplasms 1Depressive Disorder 1Caregiver Distress 1Carcinoma, Non-Small-Cell Lung 1Agnosia 1

Interventions

Carboplatin 361Pemetrexed 276Cisplatin 230Paclitaxel 213Docetaxel 205Gemcitabine 160Erlotinib Hydrochloride 150Bevacizumab 132pembrolizumab 129Radiotherapy 114Nivolumab 88durvalumab 84Drug Therapy 84osimertinib 82atezolizumab 58Vinorelbine 53Gefitinib 53Radiosurgery 50Cetuximab 39Taxes 37130-nm albumin-bound paclitaxel 36Ipilimumab 34anlotinib 33Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 33Etoposide 30Albumin-Bound Paclitaxel 29tislelizumab 27icotinib 27aflutinib 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Non-Small-Cell Lung × Psilocybin × Clear all
NCT07216404 2026-05-14

Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer

Ohio State University Comprehensive Cancer Center

Phase 2 Recruiting
10 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Depressive Disorder

Data powered by HemOnc (CC BY 4.0) Colophon âš¡